Cytek Biosciences (CTKB) Q3 2026 earnings review
Cytek Biosciences lifts its profit per machine, but legal bills widen its loss
Cytek Biosciences, a maker of cell-analysis machines and chemical supplies, lifted its gross margin while revenue barely grew. Sales edged up 2% to $53 million as 12% growth in the US and rising service contracts offset lower overseas demand. Chief executive Wenbin Jiang kept the middle of the full-year sales plan unchanged, which by our math requires a 20% jump in the fourth quarter.
| Revenue | $53.2M +1.8% from a year ago |
|---|---|
| Gross margin | 59% +5.9 percentage points from a year ago |
| EBITDA, excluding one-offs | $0.7M $2.5M a year ago |
| Full-year revenue outlook | Unchanged middle of the range: $209.5M (+4%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a genuine recovery in product gross margin was cancelled out by rising legal overhead and a mixed patent verdict. Keeping a 59% gross margin without last quarter's tariff refund resolved the concern about manufacturing profitability, but legal bills pushed nine-month profit excluding one-offs down to a $10 million loss and put full-year break-even out of reach.
The question now is whether Cytek's expanding base of installed machines can drive faster chemical supply sales or whether per-machine spending will keep shrinking. Growth bulls see a steady service business reaching 36% of sales, while sceptics see chemical sales stalling and legal exposure lingering on one lost patent claim. Fourth-quarter profit and the quarterly filing's legal footnote will tell.
🐂 Bull Case
Gross Margin Reached 59% Without Tariff Help
Cytek makes cell-analysis instruments and the chemical supplies that run on them. For the past year, its gross margin sat between 51% and 53% once one-time items were stripped out. Last quarter, gross margin reached 59% only because the US company collected a one-time tariff refund that added six percentage points.
This quarter, gross margin stayed at 58.6%, up 5.9 percentage points from a year ago, with no refund mentioned in the release. Cost of sales — the cost of making products and delivering maintenance — dropped by 5.9 percentage points of revenue to 41.4%. Product gross margin jumped 7.7 percentage points to 61.2%, and gross margin excluding one-offs rose 6 percentage points to 61%.
That matters because two straight quarters at 59% show that higher-end machines and growing service contracts are lifting profitability on their own. What to watch: product cost of sales in the quarterly filing. That disclosure will show whether factory efficiency or lower material costs drove the 7.7-point jump.
US Recovery and High-End Machines Carry Sales
"Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year," chief executive Wenbin Jiang said. Full Spectrum Profiling is Cytek's core technology for identifying cells using light, and Aurora Evo is its newer high-end analyzer.
US sales rose 12% from a year ago, marking a third straight quarter of double-digit domestic growth after 32% in the first quarter and 18% in the second. Service revenue — maintenance contracts on installed machines — climbed 13.3% to $16.1 million. Those two gains offset a 2.5% drop in total product revenue, keeping overall sales up 1.8%. What to watch: customer group tables in the quarterly filing, which will show whether drugmakers and research contractors kept growing near last quarter's 22% pace.
🐻 Bear Case
Legal Costs Push Full-Year Break-Even Out of Reach
Cytek's operating costs have outpaced its revenue all year, and management softened its full-year profit goal last quarter to roughly break-even EBITDA excluding one-offs. In the third quarter, operating expenses rose 7.9% to $39.6 million against 1.8% revenue growth. General and administrative overhead climbed 13.9% to $18.4 million, rising 3.7 percentage points to 34.5% of revenue.
The company blamed "higher litigation-related expenses, partially offset by lower compensation and severance expenses", while research costs rose on "higher personnel costs, offset by lower engineering expenses". Because overhead ate up the gross profit gain, EBITDA excluding one-offs fell to $0.7 million from $2.5 million a year ago. Over nine months, that profit measure sits at a $9.9 million loss, so by our math Cytek needs $9.9 million of fourth-quarter profit to break even — more than double last year's $4.5 million.
What to watch: general and administrative expense in the fourth quarter. A drop after the August patent trial would show how much of the cost increase was temporary legal bills.
Recurring Revenue Per Machine Keeps Falling
Cytek pitches its growing base of installed machines as an engine that pulls through recurring sales of service contracts and reagents, the chemical kits used in each cell test. Bullish investors point to recurring sales reaching 36% of trailing twelve-month revenue, up from 33% a year ago. In the third quarter, the installed base reached 4,073 instruments, up 17.9% from a year ago after adding 140 units.
- Machines added in Q3: 140 units, down from 161 a year ago
- Quarterly recurring revenue per machine: about $4,690 by our math, down from $4,700 in Q2
- Implied reagent revenue: about $3.0 million by our math ($19.1 million recurring minus $16.1 million service)
For a second straight quarter, the release omitted standalone reagent growth after highlighting it throughout 2025. By our math, service revenue per installed machine fell 3.8% from a year ago, and implied reagent revenue barely moved from last quarter's $2.9 million. What to watch: standalone reagent commentary on the earnings call, because another omission confirms chemical sales have stalled.
Jury Finds Infringement on One Patent Claim
Cytek has been fighting a patent lawsuit in Delaware targeting its core cell analyzers. On August 21, the jury ruled in the company's favor on three of four claims, finding them both invalid and not infringed. However, on the fourth claim, the jury "found no literal infringement but did find infringement under the doctrine of equivalents".
The cell-analysis group filed post-verdict motions and plans to "pursue all available legal remedies, including a potential appeal". While winning three claims avoids a worst-case shutdown, losing the fourth keeps legal costs running and leaves potential damages or royalty payments unresolved. What to watch: the footnote on legal contingencies in the quarterly filing, which will show whether Cytek must book a financial reserve for the fourth claim.
Risks this quarter didn't answer
Four standing concerns could not be fully read from the earnings release alone, though the headline numbers show overseas pressure continues.
- European and Asian sales: not split out in the release, but 12% US growth and 1.8% total growth mean sales outside the US fell about 9% from a year ago by our math; the filing's geographic table will show if Europe shrank for a seventh quarter.
- Fourth-quarter comparison hurdle: the full-year outlook requires $64.0 million in Q4 by our math, a 20.2% jump from Q3 against last year's record $62.1 million quarter.
- China export controls and tariffs: no update in the release; call commentary will show whether higher import duties hurt demand.
- Academic and government customers: vertical revenue splits were not in the release and await the quarterly filing.
💲 Other KPIs
Deferred revenue — cash customers have paid for service contracts and products not yet delivered — rose 8.8% from a year ago and 3.7% from last quarter, by our math summing current and noncurrent balances. After staying flat in the first half of 2026, this contract backlog is growing again and outpacing total sales.
Cash, restricted cash and marketable securities fell by $5.7 million from the second quarter and $5.2 million since the start of the year. After holding steady near $262 million in the first half of 2026, the cash balance dipped as operating losses and litigation bills continued.
Weighted-average diluted shares rose 2.2% from a year ago and 0.7% from the second quarter. Because Cytek paused its share buybacks last year while continuing to pay employees in stock, the share count is climbing every quarter.
🔮 Guidance
Unchanged at the middle of the range. Cytek narrowed its full-year sales plan by $1 million on each side, keeping the middle at $209.5 million, or 4.0% growth from a year ago. By our math, that leaves $64.0 million for the fourth quarter — up 20.2% from the third quarter and up 3.0% against last year's record $62.1 million fourth quarter.
❓ Key Questions
Did Cytek finish its three-unit reorganization on time?
Management previously committed to splitting the business into three units — Research Technology, Solutions and Clinical, and Service — by the third quarter of 2026. The release did not mention the reorganization or whether severance costs are finished.
Does management still expect break-even EBITDA for 2026?
Last quarter, the finance chief guided to roughly break-even EBITDA excluding one-offs for the full year. The third-quarter release gave no profit outlook, and reaching break-even now requires $9.9 million in the fourth quarter.
Why did Cytek omit reagent growth for a second quarter?
Management reported standalone chemical reagent growth every quarter in 2025 and the first quarter of 2026, then stopped. Subtracting service from recurring revenue leaves about $3.0 million of reagent sales, suggesting growth has stalled.
How much did the August patent trial cost in Q3?
General and administrative expenses rose 14% from a year ago to $18.4 million on legal bills. Investors need the exact litigation dollar amount to know what Cytek's normal cost base looks like after the trial.